Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth - Stryker (NYSE:SYK)

Summary by Benzinga
Wall Street analysts rerated Stryker Corp (NYSE:SYK) Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the analyst consensus estimate of $3.87. The company reported quarterly sales of $6.44 billion, up by 10.7%, which beat the analyst consensus estimate of $6.36 billion. Also Read: Nasdaq Touts 10% Revenue Growth In Q4, Sets 2025 Expense And Tax Guidance Several analysts rerate…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

CFO

CFO

Wall Street

Wall Street

Portage, Michigan

Portage, Michigan

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal